Fennec Pharmaceuticals publishes corporate presentation highlighting PEDMARK expansion for cisplatin-induced hearing loss prevention
FENC•Corporate presentation highlights PEDMARK expansion
Fennec Pharmaceuticals highlighted PEDMARK as the only FDA-cleared therapy to cut cisplatin-induced ototoxicity risk in pediatric patients.
The presentation cited about a 50% reduction in hearing loss with PEDMARK, with no compromise to cancer treatment in supporting trials.
U.S. market protection was outlined through September 1, 2033, with a European pediatric marketing authorization covering 10 years.
Global expansion plans include a European partnership with Norgine, Japan registration preparation, and a GCC partnership with InPharmus.
The commercial update pointed to 7 consecutive quarters of revenue growth.
